DAX19.885 -0,4%ESt504.862 -0,3%Top 10 Crypto15,15 +0,4%Dow42.985 +1,5%Nas19.637 +1,4%Bitcoin92.770 -1,7%Euro1,0423 +0,6%Öl73,11 +0,6%Gold2.626 +1,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Tesla A1CX3T NVIDIA 918422 Novo Nordisk A3EU6F Volkswagen (VW) vz. 766403 MicroStrategy 722713 Rheinmetall 703000 Amazon 906866 Palantir A2QA4J Bayer BAY001 Apple 865985 Siemens Energy ENER6Y Deutsche Bank 514000 Mercedes-Benz Group (ex Daimler) 710000 Allianz 840400 RWE 703712
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Großer Verfallstag: DAX geht tiefer ins Wochenende -- Novo Nordisk-Therapie enttäuscht in Studie -- Bitcoin fällt tief -- Covestro fliegt aus dem DAX -- D-Wave, FedEx im Fokus
Top News
KW 51: So haben sich die 40 DAX-Aktien in der vergangenen Woche bewegt KW 51: So haben sich die 40 DAX-Aktien in der vergangenen Woche bewegt
Zuversicht in New York: NASDAQ Composite am Mittag mit grünem Vorzeichen Zuversicht in New York: NASDAQ Composite am Mittag mit grünem Vorzeichen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
LAST MINUTE GESCHENK mit Herz und Verstand: Der FLEXINVEST JUNIOR-SPARPLAN. Hier KOSTENLOS abschließen & bis zu 75 € Amazon.de* Gutscheine erhalten!

Eli Lilly Aktie

NeuKaufenVerkaufen
Eli Lilly Aktien-Sparplan
761,90 EUR +31,40 EUR +4,30 %
FSE
783,51 USD +26,08 USD +3,44 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.698,50 Mrd. EUR

KGV100,48Div. Rendite0,78%

WKN858560

ISINUS5324571083

SymbolLLY

Eli Lilly Aktien News

DatumMeistgelesen
PR NewswireLilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA
PR NewswireCHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)
RSSStatement of changes in beneficial ownership of securities
RSSStatement of changes in beneficial ownership of securities
RSSStatement of changes in beneficial ownership of securities
PR NewswireLilly to Participate in UBS Global Healthcare Conference 2022
PR NewswireFDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes
PR NewswireFDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
PR NewswireMary Lynne Hedley Elected to Lilly Board of Directors
PR NewswireLilly to Participate in Bank of America Securities 2022 Healthcare Conference
MyDividendsEli Lilly meldet Dividende für das zweite Quartal
PR NewswireLilly Declares Second-Quarter 2022 Dividend
PR NewswireSolid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022
PR NewswireLilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1
PR NewswireLilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement
RSSForm 4 59478
PR NewswireLilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
RSSForm 4 59478
PR NewswireLilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress
RSSForm 4 59478
PR NewswireInnovent and Lilly Expand Strategic Partnership in Oncology
PR NewswireInnovent and Lilly Expand Strategic Partnership in Oncology
PR NewswireNearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies
PR NewswireMajority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies
PR NewswireLilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer
RSSStatement of changes in beneficial ownership of securities
RSSForm 4 59478
PR NewswireJardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
PR NewswireLilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR)
RSSForm 4 59478
PR NewswireLilly to Participate in Barclays Global Healthcare Conference
PR NewswireJardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial
PR NewswireLilly to Participate in Cowen Health Care Conference
PR NewswireUS FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
RSSForm 4 59478
PR NewswireLilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site
PR NewswireNearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study
PR NewswireLilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
RSSForm 4 59478
PR NewswireLilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options

Eli Lilly News

Eli Lilly News: auf dieser Seite finden Sie alle Eli Lilly News und Nachrichten zur Eli Lilly Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Eli Lilly News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Eli Lilly News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.